share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4:持股變動聲明-董事 Borgeson Blake
美股sec公告 ·  07/25 18:19
Moomoo AI 已提取核心訊息
Blake Borgeson, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on July 23, 2024. The transaction was executed on the open market at a price of $8.4774 per share, resulting in a total sale value of approximately $97,040.80. Following the sale, Borgeson's direct holdings in the company amount to 7,155,663 shares. The sale reflects a transaction in the company's common stock and is part of the normal course of trading activities.
Blake Borgeson, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on July 23, 2024. The transaction was executed on the open market at a price of $8.4774 per share, resulting in a total sale value of approximately $97,040.80. Following the sale, Borgeson's direct holdings in the company amount to 7,155,663 shares. The sale reflects a transaction in the company's common stock and is part of the normal course of trading activities.
Blake Borgeson,與Recursion Pharmaceuticals,Inc. [RXRX]相關聯,在2024年7月23日完成了對11447股A類普通股的銷售。該交易以8.4774美元每股的價格在公開市場上執行,結果總銷售額約爲97,040.80美元。銷售完成後,Borgeson在公司的直接持股總數爲7,155,663股。這次銷售反映了該公司普通股的交易活動,屬於正常交易活動的一部分。
Blake Borgeson,與Recursion Pharmaceuticals,Inc. [RXRX]相關聯,在2024年7月23日完成了對11447股A類普通股的銷售。該交易以8.4774美元每股的價格在公開市場上執行,結果總銷售額約爲97,040.80美元。銷售完成後,Borgeson在公司的直接持股總數爲7,155,663股。這次銷售反映了該公司普通股的交易活動,屬於正常交易活動的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息